SFRP5 and ovarian cancer: Epigenetic silencing of SFRP5 led to oncogenic activation of the Wnt pathway and contributed to ovarian cancer progression and carboplatin resistance through the transcription factor Twist-mediated EMT and AKT2 signaling.